TrialNature medicine2018

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.

David F McDermott et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.